Comparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis Model
Tóm tắt
We used a severe challenge model that produces clinical West Nile virus (WNV) disease to test the efficacy of three commercially available equine WNV vaccines in horses. Twenty-four healthy, WNV-seronegative horses of varying ages and genders were placed, in random and blind manner, into three trial groups consisting of eight horses each; two horses in each group received (i) an inactivated WNV vaccine (K-WN), (ii) a modified-live vaccine (CP-WN) containing the WNV prM and E proteins expressed by a canarypox vector, (iii) a live-chimera vaccine (WN-FV) containing WNV prM and E proteins expressed in a YF17D vector, or (iv) a diluent control. Challenge by this model caused grave neurological signs, viremia, moderate to severe histopathologic lesions in the brain and spinal cord, and an outcome of 0% survivorship in all six control horses. In contrast, challenge in horses at between 28 days postvaccination with the chimera vaccine and 56 days postvaccination with the commercial inactivated or modified-live vaccine resulted in 100% survivorship (protection from the onset of WNV encephalitis and viremia). Horses vaccinated with the live-chimera vaccine showed significantly fewer clinical signs than did the control horses (
Từ khóa
Tài liệu tham khảo
USDA animal health monitoring and surveillance: equine West Nile virus surveillance data. 2007
Beaty, B. J., C. H. Calisher, and R. E. Shope. 1989. Arboviruses, p. 797-856. In N. H. Schmidt and R. W. Emmons, Diagnostic procedures for viral, rickettsial, and chlamydial infections, 6th ed. American Public Health Association, Washington, DC.
Efficacy of a live attenuated chimeric West Nile virus vaccine in horses against clinical disease following challenge with virulent West Nile virus 2004
Bunning, M. L., R. A. Bowen, C. B. Cropp, K. G. Sullivan, B. S. Davis, N. Komar, M. S. Godsey, D. Baker, D. L. Hettler, D. A. Holmes, B. J. Biggerstaff, and C. J. Mitchell. 2002. Experimental infection of horses with West Nile virus. Emerg. Infect. Dis.8:380-386.
West Nile virus: statistics surveillance and control. 2007
Davidson, A. H., J. L. Traub-Dargatz, R. M. Rodeheaver, E. N. Ostlund, D. D. Pedersen, R. G. Moorhead, J. B. Stricklin, R. D. Dewell, S. D. Roach, R. E. Long, S. J. Albers, R. J. Callan, and M. D. Salman. 2005. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc.226:240-245.
Diamond, M. S., B. Shrestha, E. Mehlhop, E. Sitati, and M. Engle. 2003. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol.16:259-278.
Gardner, I. A., S. J. Wong, G. L. Ferraro, U. B. Balasuriya, P. J. Hullinger, W. D. Wilson, P. Y. Shi, and N. J. MacLachlan. 2007. Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California. Vet. Res.38:109-116.
Grosenbaugh, D. A., C. S. Backus, K. Karaca, J. M. Minke, and R. M. Nordgren. 2004. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet. Ther.5:251-257.
Guirakhoo, F., Z. X. Zhang, T. J. Chambers, S. Delagrave, J. Arroyo, A. D. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology257:363-372.
Hayes, E. B. 2005. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis.11:1174-1179.
Kumar, P., P. D. Uchil, P. Sulochana, G. Nirmala, R. Chandrashekar, M. Haridattatreya, and V. Satchidanandam. 2003. Screening for T cell-eliciting proteins of Japanese encephalitis virus in a healthy JE-endemic human cohort using recombinant baculovirus-infected insect cell preparations. Arch. Virol.148:1569-1591.
Efficacy duration and onset of immunogenicity of a West Nile virus vaccine live flavivirus chimera in horses with an experimentally induced clinical disease challenge model.
Minke, J. M., L. Siger, K. Karaca, L. Austgen, P. Gordy, R. Bowen, R. W. Renshaw, S. Loosmore, J. C. Audonnet, and B. Nordgren. 2004. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch. Virol. Suppl.18:221-230.
Monath, T. P., F. Guirakhoo, R. Nichols, S. Yoksan, R. Schrader, C. Murphy, P. Blum, S. Woodward, K. McCarthy, D. Mathis, C. Johnson, and P. Bedford. 2003. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis.188:1213-1230.
Monath, T. P., J. Liu, N. Kanesa-Thasan, G. A. Myers, R. Nichols, A. Deary, K. McCarthy, C. Johnson, T. Ermak, S. Shin, J. Arroyo, F. Guirakhoo, J. S. Kennedy, F. A. Ennis, S. Green, and P. Bedford. 2006. A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA103:6694-6699.
Ostlund, E. N., R. L. Crom, D. D. Pedersen, D. J. Johnson, W. O. Williams, and B. J. Schmitt. 2001. Equine West Nile encephalitis, United States. Emerg. Infect. Dis.7:665-669.
Porter, M. B., M. T. Long, L. M. Getman, S. Giguere, R. J. MacKay, G. D. Lester, A. R. Alleman, H. L. Wamsley, R. P. Franklin, S. Jacks, C. D. Buergelt, and C. J. Detrisac. 2003. West Nile virus encephalomyelitis in horses: 46 cases (2001). J. Am. Vet. Med. Assoc.222:1241-1247.
Salazar, P., J. L. Traub-Dargatz, P. S. Morley, D. D. Wilmot, D. J. Steffen, W. E. Cunningham, and M. D. Salman. 2004. Outcome of equids with clinical signs of West Nile virus infection and factors associated with death. J. Am. Vet. Med. Assoc.225:267-274.
Savage, H. M., C. Ceianu, G. Nicolescu, N. Karabatsos, R. Lanciotti, A. Vladimirescu, L. Laiv, A. Ungureanu, C. Romanca, and T. F. Tsai. 1999. Entomologic and avian investigations of an epidemic of West Nile fever in Romania in 1996, with serologic and molecular characterization of a virus isolate from mosquitoes. Am. J. Trop. Med. Hyg.61:600-611.
Schuler, L. A., M. L. Khaitsa, N. W. Dyer, and C. L. Stoltenow. 2004. Evaluation of an outbreak of West Nile virus infection in horses: 569 cases (2002). J. Am. Vet. Med. Assoc.225:1084-1089.
Siger, L., R. Bowen, K. Karaca, M. Murray, S. Jagannatha, B. Echols, R. Nordgren, and J. M. Minke. 2006. Evaluation of the efficacy provided by a recombinant canarypox-vectored equine West Nile virus vaccine against an experimental West Nile virus intrathecal challenge in horses. Vet. Ther.7:249-256.
Siger, L., R. A. Bowen, K. Karaca, M. J. Murray, P. W. Gordy, S. M. Loosmore, J. C. Audonnet, R. M. Nordgren, and J. M. Minke. 2004. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am. J. Vet. Res.65:1459-1462.
Tesh, R. B., J. Arroyo, A. P. Travassos da Rosa, H. Guzman, S. Y. Xiao, and T. P. Monath. 2002. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg. Infect. Dis.8:1392-1397.
Turell, M. J., M. Bunning, G. V. Ludwig, B. Ortman, J. Chang, T. Speaker, A. Spielman, R. McLean, N. Komar, R. Gates, T. McNamara, T. Creekmore, L. Farley, and C. J. Mitchell. 2003. DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus). Emerg. Infect. Dis.9:1077-1081.
Ward, M. P., M. Levy, H. L. Thacker, M. Ash, S. K. Norman, G. E. Moore, and P. W. Webb. 2004. Investigation of an outbreak of encephalomyelitis caused by West Nile virus in 136 horses. J. Am. Vet. Med. Assoc.225:84-89.